三阴性乳腺癌中PD-L1（22C3）和PD-L1（SP142）的表达比较及临床意义
[Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
作者信息
Zhang J, Yuan P, Lei H Z, Liu X Y, Li X, Ying J M, Sun G Y, Wang S L, Lyu N
机构信息
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Radiotherapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhonghua Zhong Liu Za Zhi. 2022 Mar 23;44(3):260-267. doi: 10.3760/cma.j.cn112152-20200803-00704.
To investigate the expression of programmed death ligand-1 (PD-L1, SP142) and PD-L1 (22C3) in triple-negative breast cancer (TNBC), and analyze their correlation with the clinicopathological factors and prognosis. The clinicopathologic data of 259 patients with TNBC treated in Cancer Hospital from August 2010 to December 2013 were collected. Whole section of surgical tissue samples were collected to conduct PD-L1 (SP142) and PD-L1 (22C3) immunohistochemical (IHC) staining. The PD-L1 expression in tumor cells and tumor infiltrating immune cells were visually assessed respectively, the relationship between PD-L1 expression and clinicopathologic characterizes were analyzed. Univariable and multivariable Cox proportional hazards regression models were used to test the correlations between PD-L1 expression and disease-free survival (DFS) and overall survival (OS). The positive rates of SP142 (immune cell score, ICs≥1%) and 22C3 (combined positive score, CPS≥1) were 42.1%(109/259) and 41.3%(107/259) in TNBC tissues, respectively, with a total coincidence rate of 82.3%. The value of positive expression cases was 0.571 and the distribution difference of SP142 and 22C3 positive expression cases was statistically significant (<0.001). The PD-L1 positive patients were less likely to have vascular invasion (<0.05), but with higher histological grade and Ki-67 proliferation index (<0.05). The recurrence/metastasis cases(8) of the patients with positive PD-L1 (SP142) was significantly lower than that of patients with negative PD-L1(SP142, 27, =0.016). The positive expression of PD-L1 (SP142) patients were longer DFS (=0.019). The OS of patients with positive PD-L1 (SP142) were longer than those with negative PD-L1 (SP142), but without significance (=0.116). The positive expression of PD-L1 (22C3) was marginally associated with DFS and OS of patients (>0.05). The expression of PD-L1 (22C3) is different from that of PD-L1 (SP142) in TNBC, and the two antibodies can't be interchangeable for each other in clinical tests. PD-L1 (SP142) status is an independent prognostic factor of DFS in TNBC. The DFS is significantly prolonged in patients with positive expression of PD-L1 (SP142).
探讨程序性死亡配体-1（PD-L1，SP142）和PD-L1（22C3）在三阴性乳腺癌（TNBC）中的表达情况，并分析其与临床病理因素及预后的相关性。收集2010年8月至2013年12月在癌症医院接受治疗的259例TNBC患者的临床病理资料。采集手术组织样本的全切片进行PD-L1（SP142）和PD-L1（22C3）免疫组织化学（IHC）染色。分别直观评估肿瘤细胞和肿瘤浸润免疫细胞中PD-L1的表达情况，分析PD-L1表达与临床病理特征之间的关系。采用单变量和多变量Cox比例风险回归模型检验PD-L1表达与无病生存期（DFS）和总生存期（OS）之间的相关性。TNBC组织中SP142（免疫细胞评分，ICs≥1%）和22C3（联合阳性评分，CPS≥1）的阳性率分别为42.1%（109/259）和41.3%（107/259），总符合率为82.3%。阳性表达病例的值为0.571，SP142和22C3阳性表达病例的分布差异具有统计学意义（<0.001）。PD-L1阳性患者发生血管侵犯的可能性较小（<0.05），但组织学分级和Ki-67增殖指数较高（<0.05）。PD-L1（SP142）阳性患者的复发/转移病例（8例）明显低于PD-L1阴性患者（SP142，27例，=0.016）。PD-L1（SP142）阳性表达患者的DFS更长（=0.019）。PD-L1（SP142）阳性患者的OS长于PD-L1（SP142）阴性患者，但无统计学意义（=0.116）。PD-L1（22C3）的阳性表达与患者的DFS和OS有边缘相关性（>0.05）。TNBC中PD-L1（22C3）的表达与PD-L1（SP142）不同，两种抗体在临床试验中不能相互替代。PD-L1（SP142）状态是TNBC中DFS的独立预后因素。PD-L1（SP142）阳性表达患者的DFS显著延长。
Zotero 插件